Identification of novel Bruton's tyrosine kinase mutations in 10 unrelated subjects with X linked agammaglobulinaemia by Brooimans, R.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/26036
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
484 J M e d  Genet 1 9 9 7 ;3 4 :4 8 4 -4 8 8
Departm ent of 
Immunology, 
University Children’s 
Hospital “H et 
W ilhelmina 
Kinderziekenhuis” ,
PO Box 18009, 3501 CA
Utrecht, The 
Netherlands
R A Brooimans 
A J A M van den Berg 
G T  Rijkers 
L A M  Sanders 
B J M Zegers
DNA Laboratory,
Clinical Genetics 
Centre Utrecht, PO  
B ox 18009* 3501 CA 
Utrecht, The 
Netherlands 
J IC Ploos van Annstel
D epartm ent of 
Pathology, University  
Hospital Utrecht, PO  
Box 85500, 3508 GA 
Utrecht, The 
Netherlands 
M  G J Tilanus
Departm ent of 
General Internal 
M edicine, Nijm egen  
University Hospital* 
PO Box 9101, 6500 HB  
Nijmegen, The 
Netherlands 
M J A L Grubben
Correspondence to:
Dr Brooimans.
Received 17 September 1996 
Revised version accepted for 
publication 30 January 1997
Identification of novel Bruton’s tyrosine kinase 
mutations in 10 unrelated subjects with X linked 
agammaglobulinaemia
Rik A Brooimans, Adrienne J A M  van den Berg, Ger T Rijkers, Lieke A M Sanders, 
Johannes K Ploos van Amstel, Marcel G J Tilanus, Marina J A L Grubben,
Ben J M Zegers
Abstract
M utations o f the B ruton’s tyrosine kinase 
(Btk) gene cause X linked agam m aglob- 
ulinaem ia (XLA). This inherited im m u­
nodeficiency disease causes an arrest in B  
cell differentiation o f pre-B  cells to m a­
ture B cells, in  this study we report the 
characterisation o f  m utations in the Btk 
gene in 10 unrelated XLA fam ilies. The 
screening approach we used was based on 
reverse transcriptase PC R  and direct 
cycle sequencing o f the am plified prod­
ucts followed by analysis o f the observed  
m utations at the level o f  genom ic DNA. 
The single strand confirm ation polym or­
phism  (SSCF) technique was used for 
assessm ent of the carriers in som e o f these  
families* Various m utations throughout 
the coding gene were observed, including  
m issense and nonsense m utations, a dele­
tion, and several splicing defects. None o f  
the m utations except one has been previ­
ously described. There were three point 
m utations resulting in a single am ino acid  
substitution. One o f these m issense m uta­
tions was observed in a conserved region  
o f the P H  dom ain, the other two were 
found in the src hom ology dom ain 2 that is  
involved in phosphotyrosyl peptide b ind­
ing. Two m utations were single base pair 
substitutions resulting in prem ature stop 
codons. In four patients abnorm al Btk 
transcripts were found that were the result 
o f  aberrant splicing. O ne sm all deletion  
was observed causing a fram eshift and a 
secondary prem ature term ination signal. 
Characterisation o f the m utations respon­
sible for XLA allowed us to diagnose the 
disease conclusively and identify the phe- 
notypically norm al fem ale carriers.
(J  M ed Genet 1997;34:484-488)
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X linked agammaglobulinaemia (XLA) was the 
first disorder of humoral immunity to be 
described as early as 1952 by B ruton .1 This 
inherited immunodeficiency is characterised 
by protracted and recurrent bacterial infec­
tions. Affected males have severely decreased 
numbers of circulating mature B lymphocytes 
and show a lack of all immunoglobulin (Ig) 
isotypes.2 In  the bone marrow the num ber of B
lymphocyte precursors, identified by Ig heavy 
chain expression in the cytoplasm, are normal 
or decreased. Therefore, XLA reflects an arrest 
in differentiation of pre-B cells to later B cell 
stages.3 The cellular defect is limited to the B 
cell line, since female XLA carriers manifest a 
unilateral X  chromosome inactivation in the 
peripheral blood B cell population.4 The disor­
der is usually diagnosed quite early in life and 
treatment consists of a lifetime of regular Ig 
infusions. In 1993 the causative gene in XLA 
was identified as a cytoplasmatic protein 
tyrosine kinase, named Bruton’s tyrosine ki­
nase (Btk) .5 6 This gene has been mapped to 
Xq21.3-Xq227 and is widely expressed 
throughout haematopoietic cell lines, including 
nearly all stages of B cell development, but is 
found at negligible levels in T  cells and is 
downregulated in plasma cells.8 The 37.5 kb 
Btk locus contains 19 exons, 18 of which code 
for a 77 kDa protein.9
Btk belongs to a subfamily of Src related 
cytoplasmatic protein tyrosine kinases (PTKs), 
including Tec II, 10 Bmx,11 Txlc, 12 Itk, 13 and Dsrc 
28C,14 also known as the Tec family. Proteins of 
the Tec family consist of five distinct structural 
domains, a unique N-terminal region, which is 
comprised of a pleckstrin homology (PH) 
domain13 and a Tec homology (TH) domain, 16 
followed by Src homology (SH) 3, SH2, and 
catalytic (SHI) domains. PH domains have 
been found in a number of proteins involved in 
intracellular signalling pathways. Protein ki­
nase C and heterotrimeric G protein have been 
proposed to bind to the Btk PH domain.17 18 
The T H  domain contains two proline rich 
regions which have been shown to interact with 
the SH3 domains of Src protein tyrosine 
kinases Fyn, Lyn, and Hck.19 Analysis of Src 
family tyrosine kinases suggests that SH2 and 
SH3 domains are involved in intermolecular 
recognition and the formation of heterodimeric 
protein complexes. SH2 domains directly 
recognise phosphorylated tyrosine residues 
and the SH3 domain is implicated in die regu­
lation of protein-protein interactions via recog­
nition of specific proline rich peptide 
sequences.20 Signal transduction pathways are 
likely to be controlled by the formation of these 
protein complexes.21
In general, the study of null mutations in a 
gene tiiat results in an inherited disorder will 
provide information about the functionally 
important domains of the gene product. In the
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Table 1 Oligonucleotide primers for the amplification o f the cD NA o f B tk
Primer Sequence Position *
BTIC A F G T  G AACT C C AG AAAGAAG AAG C T 110
BTK A R TC C TG TTC TC C A A A A TTTG G C A G 646
BTK B F CAGCCAAAAATGCTATGGGCTG 605
BTK B R AAT G AC GTAT C AC C C C T T  GAGG 1132
BTK C F GTTTGCTAAATCCACAGGGGAC 1089
BTK C R CATCCTTGCACATCTCTAGCAG 1645
BTK D F TCCAGACTCAGCAGCTGCTAG 1610
BTK D R AC C AAGAAG CTTATTG G C G AGC 2134
*The positions of the 5' nucleotide of the primers are derived from the human Btk cDNA.5
case of Btk it could indicate clues about its role 
in B cell differentiation. Furthermore, muta­
tion analysis is more accurate in diagnosing 
affected subjects and carriers, especially in 
those cases which show a milder or later onset 
of a humoral immunodeficiency in the absence 
of a family history of X linked inheritance. 
Mutations in the Btk gene have now been 
identified by several groups in about 200 unre­
lated XLA patients. Mutations reported to date 
include deletions, insertions, and missense or 
nonsense mutations and have been found in 
every domain of Btk .22 23 The first mutation 
data that were reported suggested that the 
severity of the XLA phenotype is dependent 
upon die site and nature of the m utation .9 24 25 
Now that data on so many XLA patients have 
been reported, it has become evident that there 
is no strict correlation between the site of the 
mutation and the severity of the clinical and 
immunological expression of the disease* im­
plying that odier factors might determine the 
phenotype as well.
This study was undertaken to analyse 14 
subjects from 10 unrelated families who repre­
sent either familial or sporadic cases of XLA, 
based on a clinical and immunological diagno­
sis. Here we report the characterisation of 
mutations found in the Btk gene of these sub­
jects.
Materials and m ethods
PATIENTS
Fourteen Dutch patients from 10 unrelated 
families were included in the study. All patients 
were male, aged between 2 and 38 years, and 
diagnosed as having XLA. The diagnosis of 
XLA was based on the absence or very low lev­
els of B cells in the circulation* low levels of 
immunoglobulins, and a history of recurrent 
bacterial infections.
RNA AND DNA ISOLATION
PBMCs were prepared from fresh blood by 
Ficoll (Pharmacia) separation. RNA was ex­
tracted from the PBMC fraction with RNAzol 
B(Cinna/Biotex) and used for first strand 
cDNA synthesis with AMV reverse tran­
scriptase and iSforI-d(T) l8 primer. Genomic 
DNA was purified with a QIAgen isolation kit 
according to the manufacturer’s instructions.
PCR AMPLIFICATION
PCR amplification was carried out in four 
overlapping sections using the oligonucleotide 
primer sets listed in table 1 , PC R  reactions 
were performed in a total volume of 100 p.1, 
consisting of 3 ¡llI cDNA, 50 mmol/1 KC1, 10
mmol/1 Tris-HCl, pH  8.4, 2 mmol/1 M gCl2, 50 
pmol of each primer, 0.4 mmol/1 dN TPs, and 1 
U AmpliTaq (Perkin-Elmer). Amplification 
was for 35 cycles with denaturation at 94°C, 
annealing at 60°C, and extension at 72°C, each 
for 30 seconds on a Perldn-Elmer Thermal 
Cycler system 9600.
Genomic D N A  PCR  amplification was 
carried out with the sets of primers flanking all
j
exons as reported by Vorechovsky et al*' using 
their cycling protocol with some modifications,
SEQUENCE ANALYSIS
Preamplified PC R  products were used as tem­
plates for direct cycle sequence kit (Perkin- 
Elmer) according to the manufacturer’s in­
structions.
PCR-SSCP
PC R products for single strand conformation 
polymorphism (SSCP) were generated accord­
ing the same protocol as described above. The 
detection of SSCPs was carried out on 
non-denaturating agarose gels on the PhastSys- 
tem T M  (Pharmacia,Sweden). After dilution 
1:1  in formamide loading buffer, die amplifica­
tion products were loaded onto 20% homoge­
neous phastgels (Pharmacia). Electrophoresis 
was done at 15°C at 250 Vh. DNA was visual­
ised by silver staining according to the instruc­
tions of the manufacturer.
Results
M UTATION ANALYSIS OF TH E BTK GENE
Characterisation of mutations in the Btk gene 
of XLA patients was carried out by using the 
following strategy. To identify mutations in the 
coding region of Btk, cDNA was prepared by a 
reverse transcriptase PCR reaction from pe­
ripheral blood mononuclear cells. The ampli­
fied products encompassed the coding se­
quence in four overlapping segments. The PCR 
product of each segment was directly se­
quenced by cycle sequencing. To analyse and 
confirm the identified mutations in patient 
cDNA, we amplified and sequenced patient 
genomic DNA witii primers flanking the exon 
involved. M utation analysis was performed in a 
total of 14 subjects from 10 unrelated families 
of D utch origin. Patients were diagnosed as 
classical XLA based upon the number of 
peripheral B cells and serum Ig levels. In four 
families there were two male members affected 
with X linked immunodeficiency disease; die 
other patients were sporadic cases. All patients 
analysed showed alterations in the Btk gene, 
which are summarised in table 2, Various 
mutations were observed, including insertions, 
deletions, and missense or nonsense mutations. 
Five patients manifested single point mutations 
in the coding sequence. Patient 6 showed a 
T —>C change at position 164 replacing the 
hydrophobic non-polar amino acid leucine 
with another hydrophobic non-polar amino 
acid proline, at residue 1 1 in the PH  domain. 
The L eu l 1 amino acid is strongly conserved in 
residues that form the first p sheet of known 
P H  domain sequences, like pleckstrin, spec- 
trin, and dynamin .27 In patient 4, a T —»G sub­
stitution was found at position 1218 tiiat
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Table 2 Mutations of the B tk  gene in 10 unrelated X L A  patients
Patient
Affected
relative Nucleotide change
Alteration o f coding 
sequence
Btk
domain Genomic D N A  mutation
6 + 164 T -» C L eu11Pro PH Exon 2
2 + 773-908 Aberrant splicing SH3 +1 nt intron 8 g>t
7 - 895 C -» T Arg255stop SH3 Exon 8
3 935-936 Frameshift SH2 Exon 9
8 - 1114 C —>T Gin308stop SH2 Exon 12
4 - 1218 T —>G His362Gln SH2 Exon 12
9 - 1225 A -^T Asn365Tyr Kinase Exon 12
10 + *20 nt at 1309 Aberrant splicing Kinase del +2 nt intron 13
5 + 1310-1481 Aberrant splicing Kinase + 1 nt intron 14 g>t
11 - *90 nt at 1481 Aberrant splicing Kinase +5 nt intron 14 g>a
altered residue 362 in the SH2 domain from a 
basic histidine to an uncharged glutamine. 
Based on the crystal structure of the SH2 
domain of v-src, this mutation leads to a 
disturbed phosphotyrosyl peptide binding.28 
Patient 9 also showed a missense mutation in 
the SH2 domain changing nucleotide 1225 
from A to T  causing substitution of residue 365
A
Patient 2
GTGAG
Exon 8 I
T
Exon 9
Patient 10
Exon 13
GTAAC I GTAGG 
T deleted
Exon 14
Stop
I
Patient 5 M M l P P t
m M m M É É I m GTGAG ¡SÉÉÂÉIfÉ
Exon 13 Exon 14 Exon 15
T
Patient 11
Exon 14
GTGAG I GTAAG
“ " T Exon 15
A
B
G A T C
Patient 2
A
A
G
G
A
C
G
A
A
C
A
C
C
T
D
G A T C
f a  t<Ì M . 4  :*
909
del 136 nt 
772
HR*
Patient 2
G
C
t
9
a
9
t
g
G
G
T
A
A
A
A
A
Intron 8
Exon 8
Figure 1 M utation analysis o f aberrant splicing in the B tk  gene o f X L A  subjects. (A) 
Schematic representation illustrating the aberrant splicing products in four X L A  patients. 
(B) Size analysis o f amplified cD N A product o f patient 2 (P) and a normal control. (C) 
Sequence analysis showing the deletion in the transcript o f patient 2. (D) Identification of a 
point mutation in the splice donor site o f the patient's genomic D N A .
from an amino acid asparagine for an aromatic 
tyrosine. This residue seems not to be directly 
involved in phosphotyrosyl peptide binding, 
but the effect of the mutation might be 
structural. In patient 7, a mutation C—>T at 
position 895 was identified which results in a 
premature termination signal at amino acid 
residue 255. This mutation has also been 
described in two other unrelated XLA 
patients.29 30 Patient 8 had a C ^ T  nonsense 
mutation at position 1114, giving rise to a pre­
mature stop codon at amino acid residue 308 
in the SH2 domain of Btk.
In four patients, abnormal sized Btk tran­
scripts were found, which were the result of 
aberrant splicing. Fig 1A shows a schematic 
representation of the effects of splicing muta­
tions in these patients. The larger deletions and 
insertions had already been observed by size 
analysis of the four cDNA segments in 
comparison with normal sized PCR products. 
The PCR product obtained with primers Btk B 
F and Btk B R was smaller in patient 2 (391 bp) 
than the control (527 bp) (fig IB). Sequence 
analysis of the smaller fragment showed that 
the transcript lacked nucleotides 773 to 908 
(fig 1C). According to the location of the dele­
tion or insertion in the transcript, the appropri­
ate exon-intron boundaries were sequenced 
using genomic DNA from the patient as 
template. The observed deletion in patient 2 is 
compatible with a cryptic donor splice site 
present within exon 8, indicating die loss of the 
donor splice site located downstream of the 
gene. Indeed, as shown in fig ID, genomic 
sequence analysis showed a point mutation 
G -*T involving the first nucleotide of intron 8 . 
The resulting frameshift introduced a prema­
ture termination signal 18 amino acids down­
stream of codon 213. In patient 10, a deletion 
of a T  at the +2 position of the donor splice site 
in intron 13 activated a cryptic splice 21 nucle­
otides downstream, which resulted in an inser­
tion of 20 bases encoded by intron 13 in the 
Btk transcript. The resulting frameshift intro­
duced a termination signal 17 amino acids 
downstream of codon 392. In the Btk tran­
script of patient 5, a deletion of 172 bases (nt 
1310-1481) was observed. The deleted se­
quence is encoded by exon 14, indicating an 
aberrant splicing mechanism. Sequence analy­
sis of the genomic template of this patient 
showed a nucleotide substitution G—>T at die 
+ 1 position of the donor splice junction in 
intron 14. The resulting frameshift introduced 
a stop codon 34 residues downstream of codon 
392. Patient 11 showed a G—>A change at posi­
tion +5 of intron 15, activating a cryptic donor 
splice site further downstream. This resulted in 
the addition of 90 bases of intron 15 to the Btk 
message giving rise to an immediate termina­
tion signal following codon 449. Patient 3 
manifested a deletion of two bases beginning at 
nucleotide position 934 or 935, which would 
result in a premature stop codon 3 amino acids 
downstream of codon 267.
CARRIER DETECTION WITH SSCP
With the exact mutation characterised for each 
XLA patient, we could now determine which
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P S M F
Exon 12
Figure 2 SSC P  analysis of exon 12 of the Btk gene of 
proband 6 (P) and both his parents (F-father, M~mother) 
and sister (S). The arrow indicates the mobility shift caused 
by the polymorphism. Gels were run on a Phastsystem and 
silver stained.
other relatives had inherited the same defective 
gene. This was done by using SSCP analysis 
with primer combinations flanking the exons 
involved.26 SSCP analysis of exon 12 from the 
relatives of patient 4, shown in fig 2, indicated 
that the mother of the affected boy and his sis­
ter were carriers. SSCP analysis was also 
performed for screening of the carrier status of 
female relatives of patients in family 2, 3, 6 , and 
10 (data not shown).
Discussion
In this study we have identified the mutations 
in the Btk gene of 14 p atients from 10 
unrelated families with a classical XLA pheno­
type. Mutation analysis performed in all 
patients, who were selected on the basis of 
recurrent infections or B cell levels of less than 
1 %, identified a mutation in the coding region 
of the Btk gene. The identified mutations were 
submitted to the Btk mutation database that 
has been established by Vihinen et aZ.31 All but 
one of these mutations differed from previously 
reported mutations in the BTK gene and are all 
spread throughout the gene. The mutation 
analysis approach that was chosen was based 
upon first screening patients5 cDNA and 
confirming the detected mutation on genomic 
DNA templates, especially to identify those 
mutations in which aberrant splicing is in­
volved. Others have shown that PCR-SSCP 
analysis is useful in screening for new muta­
tions in XLA patients.25 26 32 However, because 
of the genomic organisation of 19 exons which 
encompasses the entire Btk gene, one has to 
use 20 to 25 primer pairs for this analysis. 
From a cost effectiveness point of view we 
decided to use the PCR-SSCP analysis only for 
screening of carriers.
To date, in more than 200 unrelated XLA 
patients, mutations scattered all along the Btk 
gene have been identified.22 23 In this study 
three patients out of a total of 14 had a 
missense mutation. Patient 6 had a single 
amino acid substitution that is a conserved 
residue of the first (5 sheet of the PH domain. 
Several other missense mutations have been 
described located in this PH domain. Based on 
the three dimensional structure of the Btk PH 
domain these mutated residues could form a 
binding site, since most of them were located 
close to each other on the surface of the 
molecule, suggesting that this domain is 
involved in protein-protein interactions.27 33 For 
instance, Btk PH domains have been shown to 
interact with protein kinase C .17 The other two 
observed missense mutations were localised in
the SH2 domain of Btk. Alignment between 
this domain and SH 2 of v-Src indicated that 
the m utated residue 362 is directly involved in 
binding to phosphotyrosyl peptides .28
Most of the other identified mutations 
caused rearranged Btk transcripts or premature 
termination signals or both, encoding at best a 
truncated protein lacking the complete or 
functional part of the kinase domain. All of 
these patients showed the typical XLA pheno­
type with recurrent infections, B cell numbers 
less than 1%, and low serum  Ig levels. The 
splice mutation detected in XLA patient 1 1 did 
not occur in the absolutely conserved position 
of the donor splice junction ,34 leaving the 
possibility that some normal Btk transcript is 
produced. On agarose gels no normal sized 
PCR product was detectable (data not shown). 
Furthermore it has been shown by others that 
several mutations at this position abolish 
normal splicing and result in similar 
rearrangements,35"37 From various reports it has 
become clear that it is very difficult to correlate 
the nature of a m utation with the severity of the 
disease. There have been mutations found 
causing premature stop codons and frame shifts 
affecting essential domains of Btk in patients 
with clinically mild phenotypes.25 Even be- 
tween individual patients within one family 
with the same genotype, discordant phenotypes 
can o c c u r .F u r th e rm o re , a recent study has 
shown that the majority of identified muta­
tions, including missense mutations, lead to no 
detectable protein kinase activity.39 This sug­
gests that these mutations could have different 
effects on mRNA and protein stability,
XLA carriers cannot be distinguished phe- 
no typically from normal subjects. However, by 
SSCP analysis it is possible to detect an XLA 
carrier by determining the presence of a 
normal band and an altered band identical to 
that of the patient, Four families were sub­
jected to carrier analysis. Using PCR-SSCP we 
could successfully identify the carriers among 
family members (fig 2). This technique enables 
quick screening of relatives of the patient 
whether they have inherited the same defective 
gene or not and can also be used for prenatal 
diagnosis.
So far, a large am ount of data have been 
obtained on mutation analysis of the Btk gene 
in typical XLA patients and screening methods 
have become more efficient for analysis of 
patients. It would be preferable to include more 
subjects with atypical disease in these Btk 
mutation analysis studies, such as, for instance, 
patients diagnosed as having common variable 
immunodeficiency diseases (CVID), since 
there are examples of an affected Btk gene in 
some of these patients .40
In general, one can conclude that three years 
after the identification of the causative gene 
responsible for XLA., the function of Btk in B 
cell differentiation still remains to be clarified. 
To date it is evident that there is no direct cor­
relation between genotype and the clinical 
expression of the XLA phenotype, indicating 
that several other factors could play a role in 
the obs erved heterogeneity in XLA. For 
instance, genetic factors might influence the
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severity of the phenotype or past infections 
might play a role. Targeted deletion studies in 
mice have shown that the lack of Btk leads to 
impaired expression of B cell progenitors.'1142 
However., mature B cells are expressed in these 
mice3 but show defective responses to thymus 
independent type II antigens^ indicating a 
similar Xid phenotype to that observed in the 
CBA/N mice . 13 44 It seems that the difficulty in 
explaining the observed heterogeneity differ­
ences in man and mice is correlated with the 
lack of knowledge concerning the functional 
role of the Btk protein. For a better under­
standing of the pathogenesis of XLA3 it is 
therefore essential to study the expressed func­
tional Btk protein, including determination of 
substrates of Btk in the B cell and the proteins 
that interact with the Btk gene product.
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